Hikma signs agreement with EffRx for licensing of osteoporosis treatment Binesto

FTSE 250-listed pharmaceuticals group Hikma Pharmaceuticals has signed an agreement with EffRx for the licensing and distribution of osteoporosis treatment Binosto.

FTSE 250-listed pharmaceuticals group Hikma Pharmaceuticals has signed an agreement with EffRx for the licensing and distribution of osteoporosis treatment Binosto.

The treatment, which is to be distributed throughout the Middle East and North Africa (MENA), represents the only buffered solution for the treatment of osteoporosis, delivering fracture-risk reduction and offering the potential to improve adherence to therapy.

Under the terms of the agreement, Hikma will have the exclusive rights to register, market and distribute Binosto in 19 countries across MENA.

Mazen Darwazah, Vice Chairman and Chief Executive Officer of MENA for Hikma, said: "We are pleased to be licensing this excellent product from EffRx. The agreement supports our strategy to continue working with global partners to strengthen our product portfolio in growing therapeutic categories, including women's health. Hikma is committed to bringing a broad range of high quality, pharmaceutical products to patients in MENA."

Christian Rosn, Chairman and Chief Executive Officer of EffRx Pharmaceuticals said: "We are thrilled to announce this partnership with Hikma, a company who we believe to be an ideal partner for EffRx in MENA. We believe Hikma's well-established sales force across the region can drive Binosto to a market leadership position and we are extremely proud to have Hikma as a partner."

Hikma's share price was up 0.49% to 828p at 10:59.

MF

Recommended

Which assets will benefit as the “jam tomorrow” bubble pops?
Investment strategy

Which assets will benefit as the “jam tomorrow” bubble pops?

With tech stocks, cryptocurrencies and many other “long duration” investments crashing hard, the “jam tomorrow” bubble looks to be bursting. John Step…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Share tips of the week – 21 January
Share tips

Share tips of the week – 21 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
21 Jan 2022
Seven cheap defence stocks to buy now
Share tips

Seven cheap defence stocks to buy now

We’ve got used to a world without war between major powers, but that era is coming to an end as Russia threatens Ukraine and China eyes Taiwan. Buy de…
21 Jan 2022

Most Popular

Shareholder capitalism: why we must return power to listed companies’ ultimate owners
Investment strategy

Shareholder capitalism: why we must return power to listed companies’ ultimate owners

Under our system of shareholder capitalism it's not fund managers, it‘s the individual investors – the company's ultimate owners – who should be telli…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022